[Skip to Content]
[Skip to Content Landing]
Citations 0
October 15, 2003

Cost-effectiveness of Treatment for Chronic Hepatitis C InfectionCost-effectiveness of Treatment for Chronic Hepatitis C Infection

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(15):1993-1994. doi:10.1001/jama.290.15.1993-a

To the Editor: In their evaluation of the cost-effectiveness of treatment for chronic hepatitis C infection, Dr Salomon and colleagues1 pointed out that their findings are highly sensitive to alternative assumptions of the effect of both chronic HCV infection and treatment on quality of life.1 The importance of quality-of-life parameters to their models is largely due to the small proportion of their baseline cohort—40-year-old patients with chronic HCV infection—that is estimated to progress to advanced liver disease-related complications.